Tavaborole topical solution, 5% for the treatment of toenail onychomycosis.

Article Details

Citation

Copy to clipboard

Zane LT, Plattner J, Chanda S, Coronado D, Merchant T, Alley MR, Gupta AK

Tavaborole topical solution, 5% for the treatment of toenail onychomycosis.

Drugs Today (Barc). 2015 Oct;51(10):599-607. doi: 10.1358/dot.2015.51.10.2401004.

PubMed ID

26583302 [ View in PubMed

]

Abstract

Tavaborole topical solution, 5% (tavaborole) is a novel, boron-based, antifungal pharmaceutical agent indicated for treatment of toenail onychomycosis due to the dermatophytes Trichophyton rubrum or Trichophyton mentagrophytes. In preclinical studies, tavaborole effectively penetrated through full-thickness, non-diseased cadaver fingernails, including those with up to four layers of nail polish. Limited systemic absorption was observed following topical application of tavaborole. In phase III clinical trials involving patients with distal subungual onychomycosis affecting 20-60% of a target great toenail, significantly more patients treated with tavaborole versus vehicle achieved completely clear nail with negative mycology following daily application for 48 weeks. Treatment-emergent adverse events reported by at least 1% of patients treated with tavaborole and at a greater frequency versus vehicle included ingrown toenail, exfoliation, erythema and dermatitis. Treatment discontinuations were uncommon. Results from preclinical studies and phase III clinical trials establish tavaborole as a safe and efficacious treatment for toenail onychomycosis.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Tavaborole	leucine--tRNA ligase	Protein	Trichophyton rubrum	Yes	Inhibitor	Details